Chen Yu
QuietNamed in filings at Vivo Capital
- Board seats filed
- 9
- Named on a board
- 0
all filings on record
last 24 months
Named in filings at Vivo Capital
all filings on record
last 24 months
from a verified or cited source
| LB PHARMACEUTICALS | Biotech & pharma | August 2023 | None on file |
| Arbor Biotechnologies | Biotech & pharma | October 2021 | ARCH Venture Partners |
| ADARx Pharmaceuticals | Biotech & pharma | July 2020 | Caduceus Capital, Orbimed Asia Partners, Orbimed New Horizons, Orbimed Partners |
| ShouTi | Biotech & pharma | April 2019 | None on file |
| SentreHEART | Medical devices | September 2016 | U.S Venture Partners |
| Kala Pharmaceuticals | Biotech & pharma | April 2016 | Atlas Venture, Lux Capital, Third Rock Ventures |
| Outpost Medicine | Biotech & pharma | March 2016 | Passage BIO Inc, Pivotal bioVenture Partners |
| Nexcida Therapeutics | Biotech & pharma | June 2015 | None on file |
| Nora Therapeutics | Biotech & pharma | April 2014 | Third Rock Ventures |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Chen Yu on the board, based on 9 filed seats with a verified or cited source.